BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 14741772)

  • 1. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences.
    Baum C; von Kalle C; Staal FJ; Li Z; Fehse B; Schmidt M; Weerkamp F; Karlsson S; Wagemaker G; Williams DA
    Mol Ther; 2004 Jan; 9(1):5-13. PubMed ID: 14741772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
    Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
    PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development and application of gene therapy technologies].
    Ozawa K
    Uirusu; 2004 Jun; 54(1):49-57. PubMed ID: 15449904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicine. Gene therapy--new challenges ahead.
    Williams DA; Baum C
    Science; 2003 Oct; 302(5644):400-1. PubMed ID: 14563994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development.
    McCormack MP; Forster A; Drynan L; Pannell R; Rabbitts TH
    Mol Cell Biol; 2003 Dec; 23(24):9003-13. PubMed ID: 14645513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
    Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
    Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
    Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
    Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16.
    Modlich U; Schambach A; Brugman MH; Wicke DC; Knoess S; Li Z; Maetzig T; Rudolph C; Schlegelberger B; Baum C
    Leukemia; 2008 Aug; 22(8):1519-28. PubMed ID: 18496560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis.
    Modlich U; Kustikova OS; Schmidt M; Rudolph C; Meyer J; Li Z; Kamino K; von Neuhoff N; Schlegelberger B; Kuehlcke K; Bunting KD; Schmidt S; Deichmann A; von Kalle C; Fehse B; Baum C
    Blood; 2005 Jun; 105(11):4235-46. PubMed ID: 15713797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.
    Aiuti A; Cassani B; Andolfi G; Mirolo M; Biasco L; Recchia A; Urbinati F; Valacca C; Scaramuzza S; Aker M; Slavin S; Cazzola M; Sartori D; Ambrosi A; Di Serio C; Roncarolo MG; Mavilio F; Bordignon C
    J Clin Invest; 2007 Aug; 117(8):2233-40. PubMed ID: 17671653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concise review: managing genotoxicity in the therapeutic modification of stem cells.
    Baum C; Modlich U; Göhring G; Schlegelberger B
    Stem Cells; 2011 Oct; 29(10):1479-84. PubMed ID: 21898683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy insertional mutagenesis insights.
    Davé UP; Jenkins NA; Copeland NG
    Science; 2004 Jan; 303(5656):333. PubMed ID: 14726584
    [No Abstract]   [Full Text] [Related]  

  • 13. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.
    Modlich U; Bohne J; Schmidt M; von Kalle C; Knöss S; Schambach A; Baum C
    Blood; 2006 Oct; 108(8):2545-53. PubMed ID: 16825499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
    Hacein-Bey-Abina S; Garrigue A; Wang GP; Soulier J; Lim A; Morillon E; Clappier E; Caccavelli L; Delabesse E; Beldjord K; Asnafi V; MacIntyre E; Dal Cortivo L; Radford I; Brousse N; Sigaux F; Moshous D; Hauer J; Borkhardt A; Belohradsky BH; Wintergerst U; Velez MC; Leiva L; Sorensen R; Wulffraat N; Blanche S; Bushman FD; Fischer A; Cavazzana-Calvo M
    J Clin Invest; 2008 Sep; 118(9):3132-42. PubMed ID: 18688285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.
    Kustikova O; Fehse B; Modlich U; Yang M; Düllmann J; Kamino K; von Neuhoff N; Schlegelberger B; Li Z; Baum C
    Science; 2005 May; 308(5725):1171-4. PubMed ID: 15905401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation.
    Ryu BY; Evans-Galea MV; Gray JT; Bodine DM; Persons DA; Nienhuis AW
    Blood; 2008 Feb; 111(4):1866-75. PubMed ID: 17991809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Good news for gene therapy.
    Berns A
    N Engl J Med; 2004 Apr; 350(16):1679-80. PubMed ID: 15084702
    [No Abstract]   [Full Text] [Related]  

  • 18. Physiological promoters reduce the genotoxic risk of integrating gene vectors.
    Zychlinski D; Schambach A; Modlich U; Maetzig T; Meyer J; Grassman E; Mishra A; Baum C
    Mol Ther; 2008 Apr; 16(4):718-25. PubMed ID: 18334985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis.
    Kustikova OS; Schiedlmeier B; Brugman MH; Stahlhut M; Bartels S; Li Z; Baum C
    Mol Ther; 2009 Sep; 17(9):1537-47. PubMed ID: 19532134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?
    Staal FJ; Pike-Overzet K; Ng YY; van Dongen JJ
    Leukemia; 2008 Oct; 22(10):1849-52. PubMed ID: 18769449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.